SCHEMBL12401101

SCHEMBL12401101

CC(C)(C)C(=O)C(NC(=O)OCc1ccccc1Cl)C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
PKM P14618 2/20 0.48
CASP3 P42574 2/20 0.48
SENP8 Q96LD8 2/20 0.48
SENP7 Q9BQF6 2/20 0.48
SENP6 Q9GZR1 2/20 0.48
MAPT P10636 3/20 0.46
RAB9A P51151 2/20 0.46
SCN9A Q15858 2/20 0.45
SCN5A Q14524 1/20 0.45
NPC1 O15118 2/20 0.44
ALDH1A1 P00352 2/20 0.43
TACR1 P25103 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15338739 0.88 CYP1A2 (0.49) CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9
SCHEMBL15338663 0.87 CYP1A2 (0.48) CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9
SCHEMBL8145861 0.87 CYP1A2 (0.48) CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9
SCHEMBL12467351 0.86 HPGD (0.50) CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9
SCHEMBL12401155 0.85 ALDH1A1 (0.47) KMT2AMEN1MAPTRAB9ASCN9A
SCHEMBL12330595 0.84 CYP1A2 (0.46) CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9
SCHEMBL12404561 0.81 SYK (0.52) RAB9ANPC1TACR1OPRK1SMN1; SMN2
SCHEMBL5175236 0.76 ALDH1A1 (0.53) CYP1A2CYP3A4CYP2D6CYP2C19CYP2C9
SCHEMBL12401181 0.75 TGM2 (0.43) RAB9ASCN9ASCN5ANPC1ALDH1A1
SCHEMBL12401316 0.75 NAAA (0.43) KMT2AMEN1MAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575208-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-05 US disclosed
US-8440706-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-14 US disclosed
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 US disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 US disclosed
US-7985762-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 US disclosed
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-07 US disclosed
US-7964624-B1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-21 US disclosed
US-20100272681-A1 Inhibitors of Serine Proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-28 US disclosed
US-20070179167-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES PRSS1, PRSS3, PRSS2 CYP1A2 1349/4885CYP3A4 219/4885CYP2D6 1605/4885
US-20070179167-A1 Inhibitors of serine proteases PRSS1, PRSS3, PRSS2 CYP1A2 1349/4885CYP3A4 219/4885CYP2D6 1605/4885
US-20100272681-A1 Inhibitors of Serine Proteases SERPINB1, PRSS1, SPINT2 CYP1A2 1658/4885CYP3A4 527/4885CYP2D6 2137/4885
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 CYP1A2 1092/4885CYP3A4 158/4885CYP2D6 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.